CLRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectar Biosciences Inc (CLRB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown a recent positive market change of 12.50%, the lack of significant trading signals, neutral trading sentiment, and absence of recent news or financial performance data make it less compelling. Additionally, the technical indicators suggest mixed signals, with bearish moving averages and neutral RSI. The potential long-term growth indicated by analysts' price targets and positive Phase 2 data is promising, but the current market conditions do not provide a clear entry point for investment.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 70.828, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key resistance levels are at 2.805 and 2.979, with support at 2.239 and 2.065. This suggests limited upside potential in the short term.
Analysts have maintained a Buy rating with price targets of $10 and $11, citing positive Phase 2 data for iopofosine I 131 and potential for accelerated approval filing. This indicates long-term growth potential.
No recent news, neutral insider and hedge fund trading sentiment, and no significant trading trends. The stock's bearish moving averages and lack of financial performance data further add uncertainty.
No financial data available for analysis.
Analysts are positive on the stock with Buy ratings and price targets of $10 and $11, citing promising clinical trial results and potential for accelerated approval.
